Harmonisation of critical OTC derivatives data elements (other than UTI and UPI) - Technical guidance

CPMI Papers  |  No 175  | 
09 April 2018

This publication may not be the most updated technical reference.
Please see the website of the Regulatory Oversight Committee (ROC) to check for an update.

G20 Leaders agreed in 2009 that all over-the-counter (OTC) derivatives contracts should be reported to trade repositories (TRs) as part of their commitment to reforming OTC derivatives markets with the aim of improving transparency, mitigating systemic risk and preventing market abuse. Aggregation of the data reported across TRs will help ensure that authorities can obtain a comprehensive view of the OTC derivatives market and its activity.

Following the 2014 FSB Feasibility study on approaches to aggregate OTC derivatives data, the FSB asked the CPMI and IOSCO to develop global guidance on the harmonisation of data elements reported to TRs and important for the aggregation of data by authorities, including Unique Transaction Identifier (UTI) and Unique Product Identifier (UPI).

This report is one part of the CPMI-IOSCO Harmonisation Group's response to its mandate. It focuses on the definition, format and allowable values of critical data elements, other than UTI and UPI (CDE), reported to TRs and important to aggregation by authorities. The guidance is global in scale, takes account of relevant international technical standards where available and is jurisdiction-agnostic, thus enabling the consistent global aggregation of OTC derivatives transaction data.

The CPMI and IOSCO issued a Technical Guidance on Harmonisation of the Unique Transaction Identifier in February 2017 and a Technical Guidance on Harmonisation of the Unique Product Identifier in September 2017.